These data support the idea that inhibitors of Parp activity, which are currently employed in the clinic to treat certain types of breast and ovarian cancer, might potentially be repurposed for the treatment of Xrcc1-defective neurological disease. Here, PARP1 is linked to ovarian carcinoma.